We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound. We also dissect how Teledoc CEO Jason Gorevic parted ways with the company after spending 15 years building the telemedicine field. Here's where you can subscribe to our biotech newsletter, The Readout…

How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss a multibillion-dollar deal from Vertex Pharmaceuticals with sweeping implications and a lengthy backstory. We also explain why gas prices are weighing on biotech, and make a…

Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans. Here’s w…

Our colleague Sarah Owermohle joins us to explain the Supreme Court case that could have dramatic effects on access to medication abortion — and the development of new medicines. We also discuss the latest news in the life sciences, including a contrarian take on a new obesity treatment, a congressional effort to ban Chinese biotech companies, and …

Recorded live from from the STAT Breakthrough Summit East in New York City, we discuss some event highlights, including words from CRISPR pioneer Feng Zhang and Regeneron Pharmaceuticals head scientist George Yancopoulos. We also discuss the latest news in the life sciences, including a twist in the GLP-1 story, the cost of gene therapy, and, of co…

Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver…

For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots o…

We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it's such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research. Here's where you can subscribe to our biotech newsletter, The Readout. And here'…

First, former Alnylam Pharmaceuticals CEO John Maraganore and STAT’s Matthew Herper join us to discuss the legacy of AbbVie chief executive Richard Gonzalez, who announced his retirement this week. Then, we dive into the fascinating world of fetal genome surgery, as STAT’s Megan Molteni joins us to explain the work of a scientist named Tippi MacKen…

The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, in…

It's our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials. Then, we talk to Joel Dudley, a partner at the venture firm Innovation Endeavors, about how to discern promising ideas from …

We explain the debate over Vertex Pharmaceuticals' novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon. Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can…

We discuss how biotech's downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences' struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm. Subscribe to our biotech newsletter, The Readout.…

Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions. Here's where you can subsc…

Recording from the STAT co-working space outside the J.P. Morgan Healthcare Conference, we discuss how a spate of deals and some intermittent sunshine seem to have brightened the outlook for biotech at the outset of 2024. We also talk about the latest twist in the Sarepta Therapeutics saga, a ubiquitous dealmaker, and life on the party circuit. For…

It's our last episode of 2023, so we look back on the biggest stories of the year, discuss the best and worst CEOs in the industry, and make some reasonably informed guesses on what 2024 has in store for the drug industry.โดย STAT

First, we delve into the fallout over the FTC's move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics, a surprising twist that leaves unanswered question. We also discuss the latest news in the life sciences, including Pfizer’s downbeat future, Vertex Pharmaceuticals’ next big thing, and a newly minted biotech V…

With the first CRISPR-based medicine expected to win FDA approval any minute now, STAT’s Megan Molteni joins us to discuss how we got here and what it means for the future. Then, Bruce Booth from Atlas Venture joins us to discuss what was yet another downbeat year for biotech and whether there’s reason for optimism heading into 2024. To keep up wit…

We discuss why AbbVie is spending $10 billion on a cancer-focused company that spent four decades on the path to its first FDA approval, a deal with implications for biotech in 2023 and for a burgeoning area in oncology. We’ll also talk about the latest news in the life sciences, including safety concerns for CAR-T cancer treatment, the slumping in…

Our colleague Casey Ross joins us to tell the bombshell story of how the nation's largest health insurer used a computer algorithm to deny patient care and boost its profitability. Then, biotech veteran Michael Gilman calls in to offer a behind-the-scenes peek at what it’s like to be a startup CEO in this economic downturn — and which cocktail reci…

From our reporting partners at Tradeoffs: Congress banned most surprise medical bills back in 2020, with one major exception: ambulance rides. Most people agree that patients should be shielded from these unexpected charges. But who should pick up the tab instead? This week, as state and federal policymakers grapple with that question, we delve int…

As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. We also discuss the approval of Eli Lilly’s curiously named treatment for obesity, the latest implosion for a promising biotech company, and some news in the world of shareholder activism. To keep u…

Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future of Sarepta and the retirement of a biotech stalwart. For more on what we cover, here's where you can read Frank's work; here's more on Sarepta; here’s…

Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week's big oncology conference in Europe. We also discuss the latest news in the life sciences, including the future of Alzheimer’s disease treatment, a multibillion-dollar deal, and the return of the biotech mega-round. For mor…

Live from Boston at the 2023 STAT Summit, we discuss the latest news in the life sciences, including a milestone in genome editing, a twist in the search for ALS treatments, and the polarizing process of saying words in biotech.โดย STAT